Brought to you by 
Opko issues $1.4bn in stock for Bio-Reference Laboratories
18 Sep 2020
Executive Summary
Opko Health Inc. acquired publicly traded Bio-Reference Laboratories Inc. (BRLI; clinical laboratory services) for $1.4bn in stock--2.75 Opko shares (valued at $49.14, a 48% premium) for each BRLI share.
Deal Industry
- In Vitro Diagnostics
- Services
-
Laboratory Testing Services
- Anatomical Pathology
- Esoteric Laboratories
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Hematology, Coagulation
- Molecular Diagnostics & Genetic Testing
- Urine-based Testing
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Opko issues $1.4bn in stock for Bio-Reference Laboratories
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice